Galectin Therapeutics Inc. (GALT)

[Amatuer17]

GALT financials

O/s shares - 34 million
Warrants/stock options - 21 million

Fully diluted - 55 million

Only company to complete enrollment NASH-CX - other 2 closest trials will go till 2018 end

Company has 9 million cash on hand that will take it to end of year

The recent deal - Allergan bought NASH ph2 drug co for $1.7 B

If the trial results are even good - this stock can go to $5-10 and still will have market cap of $500 million

So the upside is really big but it has clear downside risk and has a extreme binary event.